Tango Therapeutics Inc TNGX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 18.14
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 140
- Website
- https://www.tangotx.com
Comparables
Valuation
|
Metric
|
TNGX
|
RLAY
|
JANX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 3.18 | 1.45 | 3.70 |
Price/Sales | 18.14 | 26.85 | 150.99 |
Price/Cash Flow | — | — | — |
Price/Earnings
TNGX
RLAY
JANX
Financial Strength
|
Metric
|
TNGX
|
RLAY
|
JANX
|
|---|---|---|---|
Quick Ratio | 7.34 | 15.28 | 57.02 |
Current Ratio | 7.49 | 15.64 | 57.34 |
Interest Coverage | — | — | — |
Quick Ratio
TNGX
RLAY
JANX
Profitability
|
Metric
|
TNGX
|
RLAY
|
JANX
|
|---|---|---|---|
Return on Assets (Normalized) | −24.41% | −28.22% | −4.75% |
Return on Equity (Normalized) | −38.87% | −32.40% | −5.12% |
Return on Invested Capital (Normalized) | −35.94% | −34.47% | −9.37% |
Return on Assets
TNGX
RLAY
JANX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Wtzhcjnqf | Jzzsf | $554.5 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Xxcrdbl | Qdksbp | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Fkkqsbfq | Kwncryc | $114.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Xyymjqb | Pypcy | $35.2 Bil | |||
| argenx SE ADR
ARGX
| Czwsbkqc | Hjlm | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Bvxwqqr | Ndhlt | $28.0 Bil | |||
| Moderna Inc
MRNA
| Pvclfnxfz | Hmqx | $24.6 Bil | |||
| United Therapeutics Corp
UTHR
| Mstvfxzp | Tcqmd | $15.9 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Wblmhfd | Wkqjzw | $13.4 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Gyrpxnyx | Dtnzsx | $12.6 Bil |
United States